Is Adialante profitable in 2026?

No. As of July 22, 2026, Adialante is pre-revenue with 4 employees, funded by a $500,000 Y Combinator investment (May 2026) and NSF SBIR grants. It targets its first paid clinic go-live in Q4 2026, so revenue has not yet materialized.

Has Adialante received FDA clearance for its MRI scanner?

No FDA clearance status has been confirmed as of July 2026. Adialante holds two issued US patents on adiabatic RF-pulse MRI hardware, but no public source confirms an FDA submission outcome, making this the single largest unresolved gate for the company.

How many people work at Adialante?

Adialante had 4 employees as of July 22, 2026, per Y Combinator's diagnostics startup directory, based in San Francisco after relocating from Minneapolis to join YC's Spring 2026 batch.

Who is Adialante's biggest competitor?

Ezra and Prenuvo are the closest rivals: Ezra had raised $41M cumulatively by February 2024 with an FDA-cleared AI enabling 30-minute scans, and Prenuvo raised $120M in February 2025, both already operating accessible whole-body MRI services Adialante has not yet launched.

Is it risky to join Adialante as an employee?

Yes. Adialante is a 4-person startup that experienced a 9-month pause on roughly $2M in federal SBIR funding in 2025, forcing a pivot into consulting work to survive, per July 10, 2026 reporting, before it had shipped any paid clinic deployment.

Is Adialante raising money right now?

Yes. As of July 10, 2026, Adialante was actively raising a seed round targeting $15-20M, which the company said it expected to close within weeks, according to reporting on its move to Silicon Valley.

YC Spring 2026 · United States

Adialante

Adialante builds low-cost, no-capex mobile MRI scanners for cancer screening in clinics.

Losing its protection

Assessed 27 July 2026 · Evidence as of 27 July 2026

The structural protection is eroding.

On the recordSince 27 July 2026 · Checkable from Q4 2026 · Every call on the record Checkpoint: First paid clinic go-live converting signed LOIs into revenue

The call

Adialante has cheap, patented hardware and paper LOIs, but no FDA clearance and no live clinic revenue yet.

Adialante builds smaller, movable MRI machines designed for specialty clinics that cannot afford traditional large scanners. The company has real patents and a narrow target market that bigger MRI makers like GE and Siemens are slow to serve, but faster-moving rivals Ezra and Prenuvo already sell FDA-approved portable imaging to similar customers and are growing their business. The one thing that matters most: whether the FDA approves Adialante's scanner design within the next 12 to 18 months, because without that approval the company runs out of time and money before it can prove doctors will actually buy and use its machines instead of choosing competitors who already have proven products on the market.

Why

AI pressure: Ezra and Prenuvo (AI-read whole-body MRI services). Their AI-driven scan reads add a diagnostic layer Adialante's hardware-only model doesn't yet offer, narrowing its edge. Could AI do the core job? Only partly.

Bigger players: GE Healthcare, Siemens Healthineers, Philips, Canon Medical. These OEMs profit from expensive scanners and service contracts, so they're slow to copy a cheap no-capex model, not blocked from it. Could a giant copy it? Probably.

What protects it. Two issued adiabatic RF-pulse patents and a sub-$1M build cost give Adialante a cost edge rivals haven't matched yet.

What would change this call

FDA clearance decision on Adialante's scanner within 12 months. Confirms or kills the regulatory moat separating it from faster-moving rivals.
Q4 2026 first clinic go-live converting LOIs to paid deployments. Shows whether signed interest turns into real, paying customers.
Ezra, Prenuvo, or Hyperfine launching a no-capex mobile-to-clinic offering. Would show a better-funded rival closing Adialante's execution window.

Key numbers

First scanner built for under $1M (2026-07-22)
$19.5-20M in LOIs signed across 11 clinics (2026-07-10)
$1.18M NSF SBIR Phase II grant awarded (2025-06)

Named risks

No confirmed FDA clearance status for Adialante's own scanner as of July 2026. Severity: high
Traction relies on non-binding LOIs ($19.5-20M, 11 clinics) not yet converted to paid revenue. Severity: high
Dependency on federal SBIR grants already caused a 9-month funding pause in 2025. Severity: medium
4-person team must simultaneously execute hardware, regulatory, and commercial launch. Severity: high
Better-funded rivals Ezra and Prenuvo could claim the no-capex mobile MRI niche first. Severity: high

Rivals, as read in July 2026

Rival	Direction	Evidence
Ezra	losing to	Ezra had $41M cumulative funding and FDA-cleared 30-min AI scans by Feb 2024 vs Adialante's pre-revenue stage
Prenuvo	losing to	Prenuvo raised $120M in Feb 2025, dwarfing Adialante's ~$3M in grants as of June 2025
Hyperfine	contesting	Public company (Nasdaq: HYPR) with FDA-cleared portable MRI and vendor-claimed >80% YoY revenue growth, recent quarter
GE Healthcare, Siemens Healthineers, Philips, Canon Medical	contesting	Adialante frames its no-capex mobile scanner as disrupting OEM scanner and service-contract pricing model, 2026

Questions people ask

Is Adialante profitable in 2026?: No. As of July 22, 2026, Adialante is pre-revenue with 4 employees, funded by a $500,000 Y Combinator investment (May 2026) and NSF SBIR grants. It targets its first paid clinic go-live in Q4 2026, so revenue has not yet materialized.
Has Adialante received FDA clearance for its MRI scanner?: No FDA clearance status has been confirmed as of July 2026. Adialante holds two issued US patents on adiabatic RF-pulse MRI hardware, but no public source confirms an FDA submission outcome, making this the single largest unresolved gate for the company.
How many people work at Adialante?: Adialante had 4 employees as of July 22, 2026, per Y Combinator's diagnostics startup directory, based in San Francisco after relocating from Minneapolis to join YC's Spring 2026 batch.
Who is Adialante's biggest competitor?: Ezra and Prenuvo are the closest rivals: Ezra had raised $41M cumulatively by February 2024 with an FDA-cleared AI enabling 30-minute scans, and Prenuvo raised $120M in February 2025, both already operating accessible whole-body MRI services Adialante has not yet launched.
Is it risky to join Adialante as an employee?: Yes. Adialante is a 4-person startup that experienced a 9-month pause on roughly $2M in federal SBIR funding in 2025, forcing a pivot into consulting work to survive, per July 10, 2026 reporting, before it had shipped any paid clinic deployment.
Is Adialante raising money right now?: Yes. As of July 10, 2026, Adialante was actively raising a seed round targeting $15-20M, which the company said it expected to close within weeks, according to reporting on its move to Silicon Valley.

Timeline

2026-07-22YC directory lists Adialante at 4 employees, based in San Francisco
2026-07-10Company reports raising $15-20M seed round; LOIs grow to $19.5-20M across 11 clinics
2026-05-13Adialante launches on YC with pitch to screen for cancer via mobile MRI
2026-05Y Combinator invests $500,000 in Adialante's Spring 2026 batch
2026-04-23Marquette University profiles co-founder Dr. Efrain Torres
2025-10-01Great Lakes I-Corps reports Adialante's NSF SBIR Phase II award
2025-06NSF awards Adialante a $1.18M SBIR Phase II grant
2025Nine-month pause on ~$2M SBIR funding forces consulting pivot ('cockroach mode')
2024-03-14University of Minnesota CTSI awards Adialante $148,000 grant

Revision history

27 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

Trellis Surtr Defense Systems HeyClicky